Bayer Completes Phase II Study On BAY 94-9172 In Alzheimer’s Disease Imaging
Bayer Schering Pharma AG, Germany, has completed its first global Phase II study analyzing the sensitivity and specificity of BAY 94-9172 (AV1/ZK) using positron emission tomography (PET) in patients with probable Alzheimer’s disease compared to healthy volunteers. BAY 94-9172 binds to the beta amyloid protein in the brain, a pathological hallmark of Alzheimer’s disease.
More: continued here
Filed under: Alzheimer's / Dementia News XML/RSS Feed on June 19th, 2009
You must be logged in to post a comment.